Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Moderna Takes The Lead With Plan To Tackle New COVID-19 Variants

New Tweaked Booster To Enter Phase I Study

Executive Summary

Moderna has unveiled plans to develop a new booster vaccine, tweaked to meet the threat posed by the South African strain.

You may also be interested in...



US FDA v. COVID Mutants: Multi-Factorial Assessments Will Determine When Product EUAs Need To Change

Acting Commissioner Janet Woodcock offers hints as to the content of upcoming guidance on how emerging virus variants may impact vaccine and therapeutic development. US may need multivalent vaccine and multiple boosters. 

COVID-19 Windfall Will Help Pfizer Remain Top Drug Company

Pfizer said it expects its COVID-19 vaccine to generate $15bn in 2021, but the forecast appears to be an underestimation as it includes only contracted doses.

Lower Efficacy Rate Of J&J’s COVID-19 Vaccine Presents ‘Messaging Challenge’

While vaccine has efficacy rate of 74% in the US, it completely prevented hospitalizations and deaths, which Fauci says is the most important result from a public health perspective. Vaccine findings cannot be compared given emergence of variants since Moderna and Pfizer conducted their studies, Janssen global head of R&D says.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143697

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel